These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 27278241)

  • 1. Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles.
    Yang SY; Chiu MJ; Lin CH; Horng HE; Yang CC; Chieh JJ; Chen HH; Liu BH
    J Nanobiotechnology; 2016 Jun; 14(1):41. PubMed ID: 27278241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of an assay of plasma neurofilament light chain utilizing immunomagnetic reduction technology.
    Liu HC; Lin WC; Chiu MJ; Lu CH; Lin CY; Yang SY
    PLoS One; 2020; 15(6):e0234519. PubMed ID: 32530970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma α-synuclein predicts cognitive decline in Parkinson's disease.
    Lin CH; Yang SY; Horng HE; Yang CC; Chieh JJ; Chen HH; Liu BH; Chiu MJ
    J Neurol Neurosurg Psychiatry; 2017 Oct; 88(10):818-824. PubMed ID: 28550072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated Plasma and Neuroimaging Biomarkers Associated with Motor and Cognition Severity in Parkinson's Disease.
    Chen CH; Lee BC; Lin CH
    J Parkinsons Dis; 2020; 10(1):77-88. PubMed ID: 31868681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma Total α-Synuclein and Neurofilament Light Chain: Clinical Validation for Discriminating Parkinson's Disease from Normal Control.
    Lin WC; Lu CH; Chiu PY; Yang SY
    Dement Geriatr Cogn Disord; 2020; 49(4):401-409. PubMed ID: 33242863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma Extracellular Vesicle α-Synuclein Level in Patients with Parkinson's Disease.
    Chung CC; Chan L; Chen JH; Hung YC; Hong CT
    Biomolecules; 2021 May; 11(5):. PubMed ID: 34067663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of Plasma Biomarkers Using Immunomagnetic Reduction: A Promising Method for the Early Diagnosis of Alzheimer's Disease.
    Yang SY; Chiu MJ; Chen TF; Horng HE
    Neurol Ther; 2017 Jul; 6(Suppl 1):37-56. PubMed ID: 28733955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.
    Williams SM; Schulz P; Sierks MR
    Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of Assaying Carcinoembryonic Antigen in Human Serum by Using Immunomagnetic Reduction.
    Wei PL; Lee LT; Tseng LM; Huang KW
    Sci Rep; 2018 Jul; 8(1):10002. PubMed ID: 29968766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection and assessment of alpha-synuclein in Parkinson disease.
    Tsao HH; Huang CG; Wu YR
    Neurochem Int; 2022 Sep; 158():105358. PubMed ID: 35561817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eight-Channel AC Magnetosusceptometer of Magnetic Nanoparticles for High-Throughput and Ultra-High-Sensitivity Immunoassay.
    Chieh JJ; Wei WC; Liao SH; Chen HH; Lee YF; Lin FC; Chiang MH; Chiu MJ; Horng HE; Yang SY
    Sensors (Basel); 2018 Mar; 18(4):. PubMed ID: 29601532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy.
    Lee PH; Lee G; Park HJ; Bang OY; Joo IS; Huh K
    J Neural Transm (Vienna); 2006 Oct; 113(10):1435-9. PubMed ID: 16465458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental study on low-detection limit for immunomagnetic reduction assays by manipulating reagent entities.
    Yang SY; Yang CC; Horng HE; Shih BY; Chieh JJ; Hong CY; Yang HC
    IEEE Trans Nanobioscience; 2013 Jun; 12(2):65-8. PubMed ID: 23392387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Different Platform Immunoassays for the Measurement of Plasma Alpha-Synuclein in Parkinson's Disease Patients.
    Youssef P; Kim WS; Halliday GM; Lewis SJG; Dzamko N
    J Parkinsons Dis; 2021; 11(4):1761-1772. PubMed ID: 34151860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma alpha-synuclein detected by single molecule array is increased in PD.
    Ng ASL; Tan YJ; Lu Z; Ng EYL; Ng SYE; Chia NSY; Setiawan F; Xu Z; Tay KY; Prakash KM; Au WL; Tan EK; Tan LCS
    Ann Clin Transl Neurol; 2019 Mar; 6(3):615-619. PubMed ID: 30911585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced Plasmonic Biosensor Utilizing Paired Antibody and Label-Free Fe
    Mandala SHS; Liu TJ; Chen CM; Liu KK; Januar M; Chang YF; Lai CS; Chang KH; Liu KC
    Biosensors (Basel); 2021 Oct; 11(10):. PubMed ID: 34677358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decrease in plasma levels of α-synuclein is evident in patients with Parkinson's disease after elimination of heterophilic antibody interference.
    Ishii R; Tokuda T; Tatebe H; Ohmichi T; Kasai T; Nakagawa M; Mizuno T; El-Agnaf OM
    PLoS One; 2015; 10(4):e0123162. PubMed ID: 25849645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility studies for assaying alpha-fetoprotein using antibody-activated magnetic nanoparticles.
    Huang KW; Yang SY; Hong YW; Chieh JJ; Yang CC; Horng HE; Wu CC; Hong CY; Yang HC
    Int J Nanomedicine; 2012; 7():1991-6. PubMed ID: 22619536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Comparative Study of the Diagnostic Potential of Plasma and Erythrocytic α-Synuclein in Parkinson's Disease.
    Wang L; Wang G; Duan Y; Wang F; Lin S; Zhang F; Li H; Li A; Li H
    Neurodegener Dis; 2019; 19(5-6):204-210. PubMed ID: 32485710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Facile Impedimetric Analysis of Neuronal Exosome Markers in Parkinson's Disease Diagnostics.
    Fu Y; Jiang C; Tofaris GK; Davis JJ
    Anal Chem; 2020 Oct; 92(20):13647-13651. PubMed ID: 32945162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.